Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses

Molecular Therapy

Volumn 23, Issue 10, 2015, Pages 1630-1640

  Woller, Norman ^a   Gürlevik, Engin ^a   Fleischmann Mundt, Bettina ^a   Schumacher, Anja ^a   Knocke, Sarah ^a   Kloos, Arnold M ^a   Saborowski, Michael ^a   Geffers, Robert ^b   Manns, Michael P ^a   Wirth, Thomas C ^a   Kubicka, Stefan ^a,c   Kühnel, Florian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c Kreiskliniken Reutlingen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; ANTINEOPLASTIC AGENT; EPITOPE; LIGAND; ONCOLYTIC VIRUS; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; IMMUNE RESPONSE; LIVER CANCER; LUNG METASTASIS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; ISOGRAFT; METABOLISM; MUTATION; NEOPLASMS; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; VIRUS INFECTION;

ANIMALS; ANTIGENS, CD274; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION; IMMUNOTHERAPY; ISOGRAFTS; LIGANDS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTORS; TUMOR VIRUS INFECTIONS;

EID: 84943582368     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.115     Document Type: Article

References (49)

1. Topalian, SL, Hodi, FS, Brahmer, JR, Gettinger, SN, Smith, DC, McDermott, DF et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
2. Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
3. Brahmer, JR, Tykodi, SS, Chow, LQ, Hwu, WJ, Topalian, SL, Hwu, P et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465.
4. Lynch, TJ, Bondarenko, I, Luft, A, Serwatowski, P, Barlesi, F, Chacko, R et al. (2012). Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30: 2046-2054.
5. Powles, T, Eder, JP, Fine, GD, Braiteh, FS, Loriot, Y, Cruz, C et al. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558-562.
6. Leach, DR, Krummel, MF and Allison, JP (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736.
7. Yuan, J, Adamow, M, Ginsberg, BA, Rasalan, TS, Ritter, E, Gallardo, HF et al. (2011). Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 108: 16723-16728.
8. Taube, JM, Klein, A, Brahmer, JR, Xu, H, Pan, X, Kim, JH et al. (2014). Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20: 5064-5074.
9. Herbst, RS, Soria, JC, Kowanetz, M, Fine, GD, Hamid, O, Gordon, MS et al. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567.
10. Tumeh, PC, Harview, CL, Yearley, JH, Shintaku, IP, Taylor, EJ, Robert, L et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571.
11. Lennerz, V, Fatho, M, Gentilini, C, Frye, RA, Lifke, A, Ferel, D et al. (2005). The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102: 16013-16018.
12. Matsushita, H, Vesely, MD, Koboldt, DC, Rickert, CG, Uppaluri, R, Magrini, VJ et al. (2012). Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404.
13. Gubin, MM, Zhang, X, Schuster, H, Caron, E, Ward, JP, Noguchi, T et al. (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515: 577-581.
14. van Rooij, N, van Buuren, MM, Philips, D, Velds, A, Toebes, M, Heemskerk, B et al. (2013). Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31: e439-e442.
15. Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, LA Jr and Kinzler, KW (2013). Cancer genome landscapes. Science 339: 1546-1558.
16. Sjöblom, T, Jones, S, Wood, LD, Parsons, DW, Lin, J, Barber, TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
17. Segal, NH, Parsons, DW, Peggs, KS, Velculescu, V, Kinzler, KW, Vogelstein, B et al. (2008). Epitope landscape in breast and colorectal cancer. Cancer Res 68: 889-892.
18. Motz, GT and Coukos, G (2013). Deciphering and reversing tumor immune suppression. Immunity 39: 61-73.
19. DuPage, M, Mazumdar, C, Schmidt, LM, Cheung, AF and Jacks, T (2012). Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405-409.
20. Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693.
21. Woller, N, Knocke, S, Mundt, B, Gürlevik, E, Strüver, N, Kloos, A et al. (2011). Virusinduced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 121: 2570-2582.
22. Grote, D, Cattaneo, R and Fielding, AK (2003). Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colonystimulating factor expression. Cancer Res 63: 6463-6468.
23. Schulz, O, Diebold, SS, Chen, M, Näslund, TI, Nolte, MA, Alexopoulou, L et al. (2005). Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
24. Prestwich, RJ, Errington, F, Ilett, EJ, Morgan, RS, Scott, KJ, Kottke, T et al. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14: 7358-7366.
25. Rammensee, H, Bachmann, J, Emmerich, NP, Bachor, OA and Stevanovi?, S (1999). SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
26. Zhang, J, Tai, LH, Ilkow, CS, Alkayyal, AA, Ananth, AA, de Souza, CT et al. (2014). Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol Ther 22: 1320-1332.
27. Kreiter, S, Vormehr, M, van de Roemer, N, Diken, M, Löwer, M, Diekmann, J et al. (2015). Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520: 692-696.
28. Tran, E, Turcotte, S, Gros, A, Robbins, PF, Lu, YC, Dudley, ME et al. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344: 641-645.
29. Gürlevik, E, Fleischmann-Mundt, B, Armbrecht, N, Longerich, T, Woller, N, Kloos, A et al. (2013). Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. Hepatology 58: 1031-1041.
30. Rychahou, PG, Kang, J, Gulhati, P, Doan, HQ, Chen, LA, Xiao, SY et al. (2008). Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 105: 20315-20320.
31. Weber, JS, Kudchadkar, RR, Yu, B, Gallenstein, D, Horak, CE, Inzunza, HD et al. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 31: 4311-4318.
32. Castle, JC, Kreiter, S, Diekmann, J, Löwer, M, van de Roemer, N, de Graaf, J et al. (2012). Exploiting the mutanome for tumor vaccination. Cancer Res 72: 1081-1091.
33. Bridle, BW, Stephenson, KB, Boudreau, JE, Koshy, S, Kazdhan, N, Pullenayegum, E et al. (2010). Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18: 1430-1439.
34. Kottke, T, Errington, F, Pulido, J, Galivo, F, Thompson, J, Wongthida, P et al. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 17: 854-859.
35. Pulido, J, Kottke, T, Thompson, J, Galivo, F, Wongthida, P, Diaz, RM et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 30: 337-343.
36. Birsoy, K, Possemato, R, Lorbeer, FK, Bayraktar, EC, Thiru, P, Yucel, B et al. (2014). Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508: 108-112.
37. Kvistborg, P, Philips, D, Kelderman, S, Hageman, L, Ottensmeier, C, Joseph-Pietras, D et al. (2014). Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 6: 254ra128.
38. Zamarin, D, Holmgaard, RB, Subudhi, SK, Park, JS, Mansour, M, Palese, P et al. (2014). Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6: 226ra32.
39. Engeland, CE, Grossardt, C, Veinalde, R, Bossow, S, Lutz, D, Kaufmann, JK et al. (2014). CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22: 1949-1959.
40. Snyder, A, Makarov, V, Merghoub, T, Yuan, J, Zaretsky, JM, Desrichard, A et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371: 2189-2199.
41. Robbins, PF, Lu, YC, El-Gamil, M, Li, YF, Gross, C, Gartner, J et al. (2013). Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19: 747-752.
42. Yadav, M, Jhunjhunwala, S, Phung, QT, Lupardus, P, Tanguay, J, Bumbaca, S et al. (2014). Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515: 572-576.
43. Weinschenk, T, Gouttefangeas, C, Schirle, M, Obermayr, F, Walter, S, Schoor, O et al. (2002). Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62: 5818-5827.
44. Franks, LM, Carbonell, AW, Hemmings, VJ and Riddle, PN (1976). Metastasizing tumors from serum-supplemented and serum-free cell lines from a C57BL mouse lung tumor. Cancer Res 36: 1049-1055.
45. Trapnell, C, Roberts, A, Goff, L, Pertea, G, Kim, D, Kelley, DR et al. (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7: 562-578.
46. McKenna, A, Hanna, M, Banks, E, Sivachenko, A, Cibulskis, K, Kernytsky, A et al. (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res 20: 1297-1303.
47. Wang, K, Li, M and Hakonarson, H (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164.
48. Wirth, T, Zender, L, Schulte, B, Mundt, B, Plentz, R, Rudolph, KL et al. (2003). A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63: 3181-3188.
49. Mueller, SN, Jones, CM, Smith, CM, Heath, WR and Carbone, FR (2002). Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J Exp Med 195: 651-656.